<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452334</url>
  </required_header>
  <id_info>
    <org_study_id>CA210-003</org_study_id>
    <nct_id>NCT01452334</nct_id>
  </id_info>
  <brief_title>Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy</brief_title>
  <official_title>A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the side effects of treatment with the monoclonal&#xD;
      antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the&#xD;
      dose that should be recommended for use in future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Every 2 weeks until 70 days after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by maximum observed serum concentration (Cmax)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by area under the serum concentration time curve in the dosing interval [AUC(TAU)]</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by accumulation index (AI) calculated ar ratio of the AUC(TAU) at steady state and first dose</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by serum concentration achieved at the end of dosing interval (trough concentration) (Cmin)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by serum concentration achieved at the end of the infusion (Ceoinf)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of BMS-936559 as measured by the objective response rate, duration of response, and progression free survival</measure>
    <time_frame>Week 4, week 12, week 20, and every 16 weeks until confirmed disease progression assessed up to Week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-936559 as measured by the frequency of subjects with an increase in anti-drug antibody levels from baseline</measure>
    <time_frame>Baseline, weeks 3, weeks 12, weeks 20, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed death ligand 1 (PD-L1) receptor occupancy levels as measured by changes from baseline</measure>
    <time_frame>Baseline and within the first 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-936559</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559 (Anti PD-L1)</intervention_name>
    <description>Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response</description>
    <arm_group_label>Arm 1: BMS-936559</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance of 0 or 1&#xD;
&#xD;
          -  Subjects must have histological confirmation of relapsed or refractory hematologic&#xD;
             malignancy&#xD;
&#xD;
          -  Subjects with non-Hodgkin's lymphoma or Hodgkin lymphoma must have at least one&#xD;
             measureable lesion as defined by lymphoma response criteria. Tumor sites that are&#xD;
             considered measureable must not have received prior radiation therapy&#xD;
&#xD;
          -  Subjects with multiple myeloma (MM) must have detectable disease as measured by&#xD;
             presence of monoclonal immunoglobulin protein in a serum electrophoresis: IgG, IgA,&#xD;
             IgM, (M-protein ≥ 0.5 g/dl or serum IgD M-protein ≥ 0.05 g/dl) or serum free-light&#xD;
             chain or 24 hour urine with free light chain. Excluded are subjects with only&#xD;
             plasmacytomas, plasma cell leukemia, or non-secretory myeloma&#xD;
&#xD;
          -  Subjects with chronic myelogenous leukemia (CML) must have evidence of the&#xD;
             Philadelphia chromosome by polymerase chain reaction (PCR) or chromosome analysis&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  For subjects with lymphoma, either a formalin fixed tissue block or 7 to 15 slides of&#xD;
             tumor sample (archival or fresh) must be available for performance of correlative&#xD;
             studies&#xD;
&#xD;
          -  Subjects must have received at least one prior chemotherapy regimen. Subjects must be&#xD;
             off therapy for at least 4 weeks ( 2 weeks for oral agents) prior to Day 1&#xD;
&#xD;
          -  Prior palliative radiation must have been completed at least 2 weeks prior to study&#xD;
             Day 1&#xD;
&#xD;
          -  Toxicities related to prior therapy must have returned to Grade 1 or less, except for&#xD;
             alopecia. Peripheral neuropathy must be Grade 2 or less&#xD;
&#xD;
          -  Adequate bone marrow function defined as:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1000/μl (stable off any growth factor within 1 week&#xD;
                  of study drug administration)&#xD;
&#xD;
               2. Hemoglobin ≥ 9 g/dL (transfusion to achieve this level is permitted)&#xD;
&#xD;
               3. Platelet count ≥ 50 X 103/ μl (transfusion to achieve this level is not&#xD;
                  permitted)&#xD;
&#xD;
          -  Adequate renal parameters defined as Creatinine clearance (CrCl) &gt; 40 ml/min&#xD;
             (Cockcroft-Gault formula)&#xD;
&#xD;
          -  Adequate hepatic parameters defined as:&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) ≤ 3 x ULN&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) ≤ 3 x ULN&#xD;
&#xD;
               3. Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert's Syndrome, who must have&#xD;
                  total bilirubin &lt; 3.0 mg/dL and direct bilirubin &lt; 0.5 mg/dL)&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) and for at least 70 days after the last dose&#xD;
             of investigational product&#xD;
&#xD;
          -  Men and women ≥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute leukemias, blast phase CML, T cell lymphoblastic or Burkitt&#xD;
             lymphoma&#xD;
&#xD;
          -  Subjects with a history of central nervous system involvement by hematologic&#xD;
             malignancy or symptoms suggestive of central nervous system involvement&#xD;
&#xD;
          -  Subjects with concomitant second malignancies (except adequately treated&#xD;
             nonmelanomatous skin cancers, ductal carcinoma in situ, treated superficial bladder&#xD;
             cancer or prostate cancer or in situ cervical cancers) are excluded unless a complete&#xD;
             remission was achieved at least 3 years prior to study entry and no additional therapy&#xD;
             is required or anticipated to be required during the study period&#xD;
&#xD;
          -  Subjects with any active autoimmune disease or a history of known or suspected&#xD;
             autoimmune disease, or history of syndrome that requires systemic corticosteroids or&#xD;
             immunosuppressive medications, except for subjects with vitiligo or resolved childhood&#xD;
             asthma/atopy&#xD;
&#xD;
          -  A serious uncontrolled medical disorder or active infection which would impair the&#xD;
             ability of the subject to receive protocol therapy or whose control may be jeopardized&#xD;
             by the complications of this therapy&#xD;
&#xD;
          -  Prior therapy with an anti programmed death-1 (anti-PD-1), anti Programmed death&#xD;
             ligand 1 (anti-PD-L1), anti Programmed death ligand 2 (anti-PD-L2), anti-CD137 or anti&#xD;
             Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (or any other&#xD;
             antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)&#xD;
&#xD;
          -  Non-oncology vaccine therapies for prevention of infectious diseases (eg seasonal flu&#xD;
             vaccine, Human Papilloma Virus (HPV) vaccine) within 4 weeks of study drug&#xD;
             administration Vaccination while on study is also prohibited except for administration&#xD;
             of the inactivated influenza vaccine&#xD;
&#xD;
          -  Prior organ allograft or allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV 1/2) or known acquired immunodeficiency&#xD;
             syndrome (AIDS)&#xD;
&#xD;
          -  Positive tests for hepatitis B virus surface antigen (HBsAg), or antibody to hepatitis&#xD;
             B core Ag or hepatitis C virus antibody (confirmed by Western Blot) or hepatitis C&#xD;
             ribonucleic acid (RNA) in serum&#xD;
&#xD;
          -  Ejection fraction less than 45% in subjects with prior anthracycline exposure&#xD;
&#xD;
          -  History of Grade 4 anaphylactic reaction to monoclonal antibody therapy&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-936559</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

